Archivos espanoles de urologia · 1995
[Retroperitoneal fibrosis secondary to treatment with L-dopa analogues for Parkinson disease].
Клинический случайАннотация на английскомСтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sánchez-Chapado M, Angulo Cuesta J, Guil Cid M, Jiménez F J, López Alvarez Y J
Аннотация
OBJECTIVES: The present study describes two patients with retroperitoneal fibrosis following prolonged use of bromocriptine and pergolide for Parkinson's disease. Both patients also presented severe atheromatosis.
METHODS: Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.
RESULTS: Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.
CONCLUSIONS: Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.
METHODS: Similar cases reported in the literature are reviewed and the possible relationship between the use of the ergotamine derivate and severe atheromatosis is discussed.
RESULTS: Both patients, a 67-year-old male and a 62-year-old female, improved after discontinuing bromocriptine, despite severe damage of renal function.
CONCLUSIONS: Retroperitoneal fibrosis may develop in patients with bilateral ureteral obstruction, especially those who have received drugs that have been reported to cause the foregoing condition.